Bristol-Myers Squibb Company Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (48)

Latest Posts

About This Stock More About This Stock
Large Cap Biopharmaceuticals: Update On Financial Metrics
Article By: Rod Raynovich
Sunday, February 12, 2017 4:12 AM EST
We have updated the comparison of eight large cap biopharma stocks post 2016 earnings for the period ending 2/10/17. Keep in mind that in January 2016 there was a severe correction with stocks dropping 25-30% with lows being hit in February 2016.
In this article: BMY, ALXN, AMGN, CELG, GILD, ABBV, IBB, REGN Also: XBI
Read
Large Cap Biopharma: January ’17 Update
Article By: Rod Raynovich
Tuesday, January 31, 2017 9:24 PM EST
In this article, stock prices are compared for the one year bear market 1/7/16 - 1/31/17.
In this article: BMY, AMGN, CELG, GILD, XBI, ABBV Also: FBIOX, ALXN, IBB, REGN, BIIB, FBT
Read
Bristol-Myers Q4 Earnings Miss Estimates
Article By: Zacks Investment Research
Thursday, January 26, 2017 1:32 PM EST
Bristol-Myers misses on fourth-quarter 2016 earnings. The company reported EPS of 63 cents while our consensus called for EPS of 66 cents.
In this article: BMY
Read
AskSlim Market Week - Friday, January 20
Video By: Steve Miller
Friday, January 20, 2017 10:17 PM EST
Stock market index is really mixed for the week because a couple of index edged lower. Nasdaq is still the strongest index of the week as the bank stocks continued to be quite firm.
In this video: AA, AG, BK, BMY, CLF, CSX, DDD, GG, GS, NRG, TGT, NFLX, NTRS, PAAS, TSLA, GLD, UUP, SPX
Watch
Bristol-Myers Slides After Another Lung Cancer Drug Setback
Article By: The Fly
Friday, January 20, 2017 12:07 PM EST
Shares of Bristol-Myers Squibb are sliding after the company announced that it will not pursue an accelerated regulatory path for the Opdivo/Yervoy combination, with research firm Cowen downgrading the stock to Market Perform following the news.
In this article: BMY Also: MRK, AZN, RHHBY
Read

PARTNER HEADLINES

Latest Tweets for $BMY

No tweets yet!